Status:
COMPLETED
Comparison of Two Formulations of Biphasic Insulin Aspart 70
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
This trial is conducted in Europe. The aim of this trial is to compare two formulations of biphasic insulin aspart 70 and characterise the pharmacokinetics of biphasic insulin aspart 50 and biphasic i...
Detailed Description
Each subject participated in three treatment periods, and were randomly assigned to each of the six treatment sequences in varying order
Eligibility Criteria
Inclusion
- Caucasian
- Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator
- Body mass index (BMI) between 19-27 kg/m\^2
- Fasting plasma glucose between 3.8-6.0 mmol/L
Exclusion
- Participation in any other clinical trial involving other investigational products within the last three months
- Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator
- Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug
Key Trial Info
Start Date :
November 3 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 1999
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01523041
Start Date
November 3 1999
End Date
November 30 1999
Last Update
February 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Leeds, United Kingdom, LS2 9NG